EpiAxis Therapeutics Announces Search for Strategic Partners for Leadership in Epigenetic Control of Metastatic Cancer – EIN News
Mang. Const.
EpiAxis has appointed The Sage Group to lead the partnering program for its peptide candidates which modulate the epigenetic control of metastatic cancer.
Source: Mang. Const.